Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo is planning to sell its anti-bacterial drug Tavanic through Ranbaxy network in Romania and South Africa.
Subscribe to our email newsletter
Under a manufacturing agreement signed between Daiichi Sankyo and Sanofi-Aventis in 1993, Sanofi-Aventis has launched Levofloxacin in more than 90 countries as Tavanic.
Daiichi Sankyo and Sanofi-Aventis have mutually transferred the marketing rights of Tavanic in Romania and South Africa from Sanofi-Aventis to Ranbaxy, early this year.
Daiichi Sankyo and Ranbaxy said that the transfer is expected to be effective in August 2010 for Romania, and in January 2012 for South Africa.
Under the agreement, Sanofi-Aventis will continue to manufacture finished products of Tavanic for these countries. Commercialisation of Tavanic by Sanofi-Aventis remains unchanged in the other territories.
Atul Sobti, managing director and CEO of Ranbaxy, said: “Ranbaxy has a significant presence and position in Romania and South Africa. As part of our commitment to deliver greater value through the Hybrid Business Model, we are pleased to offer Tavanic, an innovative product of Daiichi Sankyo, in these markets.”